|Last Update: 05/24/13 - 12:00 PM EDT|
|YTD Performance: 14.94%|
|Previous Close: $31.75|
|52 Week Range: $20.50 - $32.09|
|Oustanding Shares: 381,089,535|
|Market Cap: 12,023,374,829|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||9||8||10||10|
|Growth Rate (Year over Year)||12.59%||7.23%||11.35%||13.42%|
MYL was downgraded from Outperform to Market Perform, Bernstein said. $33 price target. Company lacks near-term catalysts.
Barclays Healthcare Conference
Here is how I am picking apart the sectors looking for strong relative performance candidates.
MYL was downgraded to Neutral, said Canaccord. Fewer catalysts are ahead, making upside from here limited.
Shares of MYL now seen reaching $31, according to Canaccord Genuity. Estimates also upped, as the company will likely make an accretive acquisition or repurchase more stock. Buy rating.
The health sector is one the less-beaten-down areas amid market weakness.
MYL was upgraded to Outperform from Market Perform, Leerink Swann said. $30 price target. Improved outlook on EpiPen and accretive transactions.
MYL was upgraded to Buy, Canaccord Genuity said. $30 price target. Company can deliver earnings upside in the coming quarters.
Here are two generic-drug companies that should hold up well, regardless of the current uncertainty.
There's no reason to read much into it.